Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
H Döhner, EH Estey, S Amadori… - Blood, The Journal …, 2010 - ashpublications.org
In 2003, an international working group last reported on recommendations for diagnosis,
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …
Therapeutic advances in acute myeloid leukemia
A Burnett, M Wetzler, B Löwenberg - Journal of clinical oncology, 2011 - ascopubs.org
The choice of treatment approach and outcome in acute myeloid leukemia (AML) depends
on the age of the patient. In younger patients, arbitrarily defined as being younger than 60 …
on the age of the patient. In younger patients, arbitrarily defined as being younger than 60 …
Acute myeloid leukemia
B Lowenberg, JR Downing… - New England Journal of …, 1999 - Mass Medical Soc
Acute myeloid leukemia (AML) is characterized by an increase in the number of myeloid
cells in the marrow and an arrest in their maturation, frequently resulting in hematopoietic …
cells in the marrow and an arrest in their maturation, frequently resulting in hematopoietic …
Acute myeloid leukaemia
E Estey, H Döhner - The Lancet, 2006 - thelancet.com
Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haemopoietic
progenitor cells and the most common malignant myeloid disorder in adults. The median …
progenitor cells and the most common malignant myeloid disorder in adults. The median …
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
AK Burnett, NH Russell, RK Hills, J Kell… - Blood, The Journal …, 2015 - ashpublications.org
Modifying induction therapy in acute myeloid leukemia (AML) may improve the remission
rate and reduce the risk of relapse, thereby improving survival. Escalation of the …
rate and reduce the risk of relapse, thereby improving survival. Escalation of the …
Cytarabine and daunorubicin for the treatment of acute myeloid leukemia
T Murphy, KWL Yee - Expert opinion on pharmacotherapy, 2017 - Taylor & Francis
Introduction: Acute myeloid leukemia (AML) is the most common acute forms of leukemia in
adults. It has a poor long-term survival with a high relapse rate and at relapse, is commonly …
adults. It has a poor long-term survival with a high relapse rate and at relapse, is commonly …
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter …
J Holowiecki, S Grosicki, S Giebel, T Robak… - Journal of clinical …, 2012 - ascopubs.org
Purpose The goal of this study was to evaluate whether the addition of a purine analog,
cladribine or fludarabine, to the standard induction regimen affects the outcome of adult …
cladribine or fludarabine, to the standard induction regimen affects the outcome of adult …
Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia
PH Wiernik, PL Banks, DCJ Case, ZA Arlin… - 1992 - ashpublications.org
The purpose of this study was to determine the relative merits of idarubicin and daunorubicin
in acute myeloid leukemia (AML) therapy. Thirty-two sites provided 214 previously untreated …
in acute myeloid leukemia (AML) therapy. Thirty-two sites provided 214 previously untreated …
A randomized study of high-dose cytarabine in induction in acute myeloid leukemia [see comments]
JF Bishop, JP Matthews, GA Young, J Szer, A Gillett… - 1996 - ashpublications.org
High-dose cytarabine (ara-c) may overcome cytarabine resistance in leukemic blasts. It has
been used as a successful salvage and in postremission therapy but not as initial induction …
been used as a successful salvage and in postremission therapy but not as initial induction …
[HTML][HTML] Emerging therapies for acute myeloid leukemia
C Saygin, HE Carraway - Journal of hematology & oncology, 2017 - Springer
Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity.
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …